Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
152 participants
INTERVENTIONAL
2011-02-28
2013-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison Between FDG-PET and MRI for the Assessment of Response to Intensive Chemotherapy in Multiple Myeloma Patients.
NCT00200668
Interest of a Systematic One-year Monitoring by 18F-FDG PET-CT
NCT04464590
"WB-DCE-MRI" in Multiple Myeloma as an Independent Prognostic Factor for Disease-free Survival
NCT01171430
PET-CT in Lymphoma Among the Eldery
NCT07259941
18F-FDG PET Radiomics of Diffuse Large B-cell Lymphoma
NCT04317313
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PET scan
Performed at diagnosis, after 3 cycles of induction therapy, and at completion of therapy
MRI
Performed at diagnosis, after 3 cycles of induction therapy, and at completion of therapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* less than 65 years of age
* enrolled in the IFM/DFCI clinical trial
Exclusion Criteria
* not eligible for high-dose therapy
* Cons-indications to MRI or PET-Scan
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ministry of Health, France
OTHER_GOV
Nantes University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bordeaux University Hospital
Bordeaux, , France
Brest University Hospital "CHU du Morvan"
Brest, , France
Hospital "Côte de Nacre"
Caen, , France
Clermont-Ferrand University Hospital
Clermont-Ferrand, , France
Dijon University Hospital
Dijon, , France
Grenoble University Hospital "Hôpital Michallon"
Grenoble, , France
Le Mans Hospital
Le Mans, , France
Lille University Hospital "Claude Huriez"
Lille, , France
Lyon University Hospital
Lyon, , France
"Institut Paoli Calmettes"
Marseille, , France
Metz University Hospital "Hôpital de Mercy"
Metz, , France
Nancy University Hospita "Hôpitaux de Brabois"
Nancy, , France
Nantes University Hospital
Nantes, , France
APHP "Hôpital Saint-Antoine"
Paris, , France
Rennes University Hospital
Rennes, , France
Toulouse University Hospital
Toulouse, , France
Tours University Hospital "Hôpital Bretonneau"
Tours, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Zamagni E, Nanni C, Dozza L, Carlier T, Bailly C, Tacchetti P, Versari A, Chauvie S, Gallamini A, Gamberi B, Caillot D, Patriarca F, Macro M, Boccadoro M, Garderet L, Barbato S, Fanti S, Perrot A, Gay F, Sonneveld P, Karlin L, Cavo M, Bodet-Milin C, Moreau P, Kraeber-Bodere F. Standardization of 18F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma. J Clin Oncol. 2021 Jan 10;39(2):116-125. doi: 10.1200/JCO.20.00386. Epub 2020 Nov 5.
Jamet B, Morvan L, Nanni C, Michaud AV, Bailly C, Chauvie S, Moreau P, Touzeau C, Zamagni E, Bodet-Milin C, Kraeber-Bodere F, Mateus D, Carlier T. Random survival forest to predict transplant-eligible newly diagnosed multiple myeloma outcome including FDG-PET radiomics: a combined analysis of two independent prospective European trials. Eur J Nucl Med Mol Imaging. 2021 Apr;48(4):1005-1015. doi: 10.1007/s00259-020-05049-6. Epub 2020 Oct 2.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2010-A01382-37
Identifier Type: OTHER
Identifier Source: secondary_id
STIC/10/03
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.